Primobol Inject
Primobol Inject British Dragon — Overview
Primobol Inject delivers methenolone enanthate at 100 mg/ml — the injectable form of methenolone, commercially known as Primobolan Depot. Methenolone is a DHT-derived anabolic steroid with a 1-methyl group and a Δ1-double bond that together protect it from 3α-hydroxysteroid dehydrogenase inactivation in muscle tissue, preserving genuine anabolic activity despite its DHT base. Unlike the oral methenolone acetate form, the enanthate ester injectable is not 17α-alkylated — it carries no hepatotoxic burden and does not produce liver enzyme elevation at any practical dose. The enanthate ester provides a half-life of approximately 10–14 days, making once or twice weekly injection sufficient to maintain stable plasma levels throughout the cycle.
The defining characteristic of Primobol Inject is its consistently clean output: lean, dry, quality muscle gains without aromatization, without water retention, and without the estrogenic management complexity that accompanies most injectable AAS. At 400–600 mg/week, the anabolic effect is meaningful and the gains are well-retained post-cycle — not obscured by water that disappears when the compound clears. It is not a mass builder in the conventional sense; it does not produce the rapid weight accumulation of nandrolone or testosterone at high doses. Its value lies in the quality and retainability of what it builds. steroidwarehouse.com carries Primobol Inject as part of the British Dragon injectable lineup for lean cycle, cutting, and lean-bulk protocols.
About the Compound
Methenolone's structure combines two features that determine its pharmacological behavior. The 1-methyl group (adding a methyl substituent at C1 of the A-ring) and the Δ1-double bond (introducing unsaturation between C1 and C2) together make methenolone resistant to the 3α-hydroxysteroid dehydrogenase enzyme that would otherwise inactivate it in muscle. This is the same challenge faced by other DHT-derived compounds — mesterolone, for instance, is inactivated by 3α-HSD in muscle and therefore lacks direct anabolic muscle-building activity. Methenolone's structural modifications bypass this inactivation, allowing it to function as an androgen receptor agonist in skeletal muscle tissue.
The absence of 17α-alkylation in the injectable enanthate form is a clinically significant distinction from the oral methenolone acetate form. The oral form IS 17α-alkylated for bioavailability — it carries hepatotoxicity accordingly. The injectable enanthate form bypasses hepatic first-pass metabolism via intramuscular depot, requires no 17α-alkylation, and produces no hepatic enzyme elevation. This makes Primobol Inject one of the very few AAS where cycle length is not limited by hepatic tolerance — it is limited only by HPG suppression duration and overall cycle goals.
Methenolone does not aromatize. No conversion to estradiol or any estrogenic metabolite occurs. The consequences are entirely positive from a management standpoint: no aromatase inhibitor is required during a methenolone-only cycle, no gynecomastia risk, no estrogen-driven water retention. Users running Primobol Inject alongside a testosterone base will manage estrogen from the testosterone component only.
What Methenolone Does
Methenolone's anabolic output is real but dose-dependent in a way that frequently surprises users accustomed to nandrolone or testosterone benchmarks. At 200 mg/week, the anabolic effect is mild and often insufficient to produce meaningful muscle mass in trained male users beyond what a natural training response would provide. At 400 mg/week, the compound begins to deliver consistently observable gains; at 600 mg/week, the lean mass and strength improvement is clearly significant for most users. This dose-dependency is important to communicate upfront — the compound requires committed dosing to work, and underdosing is the most common reason users report disappointing results with primobolan.
- Lean, dry anabolic output — no water retention — methenolone's gains are slow by injectable AAS standards and entirely free of estrogenic water accumulation. The mass built over a 12–16 week cycle at 400–600 mg/week is lean, visible, and well-retained after the cycle. This stands in contrast to nandrolone or testosterone cycles where a meaningful fraction of weight gained during the cycle reflects water — which reverses post-cycle and reduces the apparent net result. The net result from a properly dosed methenolone cycle is fully visible and retained.
- Nitrogen retention and anti-catabolic effect — methenolone produces meaningful nitrogen retention at effective doses, supporting a positive nitrogen balance in both caloric surplus and deficit. The anti-catabolic application — preserving lean tissue during a cutting phase — is one of its most practical performance uses. At 400–600 mg/week during a caloric deficit, methenolone slows lean tissue loss and allows fat loss to proceed with minimized muscle catabolism.
- SHBG reduction — methenolone binds SHBG with high affinity, reducing the amount of sex hormone-binding globulin available to sequester free testosterone and other steroids in a stack. When Primobol Inject is run alongside a testosterone base, the SHBG reduction increases the free fraction of circulating testosterone, amplifying the effective anabolic environment beyond what either compound alone would produce.
- Mild immune-modulating properties — clinical studies on methenolone in immunocompromised patient populations documented mild immunostimulating effects. While this property is not a primary reason for its athletic use, it distinguishes methenolone from compounds with neutral or negative immune profiles and has contributed to its historical use in patient populations experiencing immune suppression.
Who It Is For
Primobol Inject is the appropriate compound for users who prioritize the quality and retainability of gains over the speed and magnitude of mass accumulation, and who want to minimize the estrogenic and hepatic management complexity that accompanies most other injectable AAS.
- Lean bulk and quality mass cycles — intermediate to advanced users — the primary male performance use. At 400–600 mg/week for 12–16 weeks alongside a moderate testosterone base, Primobol Inject builds lean, keepable muscle mass that remains visible post-cycle. Users who have previously run nandrolone or testosterone mass cycles and found themselves retaining insufficient lean mass after water dissipation get the most from switching to a methenolone-centered approach for their next cycle.
- Cutting cycles — muscle preservation under caloric restriction — the anti-catabolic nitrogen retention effect at effective doses makes methenolone one of the most practical cutting compounds in the injectable class. Bodybuilders in a contest preparation or extended fat-loss phase use Primobol Inject at 400–600 mg/week to maintain the lean mass built during the off-season while calories are restricted. The dry, no-water profile means the compound contributes to visible conditioning rather than masking it.
- Female users at conservative doses — at 50–100 mg/week, methenolone enanthate has a long history of documented female use with a manageable virilization risk profile. Its relatively low androgenicity compared to testosterone-derived injectables makes it one of the more practical injectable AAS options for female athletes who need more anabolic support than oxandrolone alone provides. Injection frequency of once weekly is practical at these doses. As with all AAS in female protocols, early signs of virilization warrant dose reduction or discontinuation.
Choose something else when: maximum mass accumulation within a short cycle window is the goal — methenolone's output at 12–16 weeks does not compete with nandrolone or high-dose testosterone for sheer mass volume. For rapid mass, Decabol 250 BD or a high-dose testosterone base is more appropriate. When budget is a primary constraint, the dose requirement for effective methenolone results (400–600 mg/wk) means higher product consumption than lower-dose effective alternatives.
Primobol vs Alternatives
| Compound | Key Differences | Choose Primobol When | Choose Alternative When |
|---|---|---|---|
| Primobol Inject British Dragon |
Methenolone enanthate 100 mg/ml; no aromatization; no hepatotoxicity; dry lean muscle and anti-catabolic output; requires 400+ mg/wk for meaningful effect; 1–2 injections per week; female-compatible at low doses | Lean quality gains over 12–16 weeks; cutting cycle muscle preservation; minimal side effect profile required; female protocol | — |
| Boldabol 200 British Dragon |
Boldenone undecylenate 200 mg/ml; also dry, no significant aromatization; stronger appetite stimulation than methenolone; more pronounced erythropoiesis (hematocrit monitoring required); longer ester (~14 days); slightly more androgenic; often compared to methenolone for lean mass cycles | Appetite stimulation needed alongside lean gains; boldenone's mild estrogenic effect is acceptable or desired; slightly more pronounced mass output | Zero aromatization and zero appetite stimulation interference; purest dry lean output → Primobol |
| Mastabol 100 British Dragon |
Drostanolone propionate 100 mg/ml; also DHT-derived and non-aromatizing; shorter ester (propionate, 2–3 day half-life → EOD or 3x/wk injection); stronger hardening and cosmetic effect in lean body fat conditions; more androgenic; no anti-catabolic nitrogen retention at lower body fat; primarily pre-contest compound; lower dose requirement than methenolone | Pre-contest hardening and cosmetic conditioning at sub-12% body fat; shorter cycle window needed; more frequent injection acceptable | Lean mass building over longer cycle; anti-catabolic protection during cut; weekly injection preferred → Primobol |
| Decabol 250 British Dragon |
Nandrolone decanoate 250 mg/ml; significant mass builder over 10–16 weeks; low but present aromatization; water retention notable at higher doses; stronger anabolic output than methenolone gram-for-gram; prolactin management required; joint-support properties; not dry | Maximum mass output over a long injectable cycle; joint support needed; heavier bulk is the objective | Dry, lean gains without water or prolactin management; cutting phase protection → Primobol |
Combinations
| Goal | Stack | Why It Works |
|---|---|---|
| Classic lean bulk | Primobol Inject (400 mg/wk, weeks 1–16) + Testabol Enanthate BD (300–400 mg/wk, weeks 1–16) + Anastrozole BD (0.25 mg EOD for testosterone component) | The textbook Primo-test lean bulk: Testabol Enanthate provides a testosterone base and HPG suppression coverage; Primobol adds the anabolic environment for lean, dry muscle building while its SHBG reduction amplifies the free testosterone fraction. Anastrozole at low frequency manages only the testosterone's aromatization — Primobol contributes no estrogen. The cycle's output is slower than a nandrolone or high-dose testosterone cycle but the retained lean mass post-cycle is higher as a proportion of total gains. |
| Pre-contest cutting stack | Primobol Inject (600 mg/wk, weeks 1–12) + Testabol Propionate BD (100 mg EOD, weeks 1–12) + Mastabol 100 BD (300 mg/wk, weeks 5–12) + Anastrozole BD (0.25 mg EOD) | All three compounds are dry with no significant aromatization contribution beyond the testosterone base. Primobol provides anti-catabolic nitrogen retention during the caloric deficit; Testabol Propionate offers a fast-clearing testosterone base appropriate for tight pre-contest cycle management; Mastabol 100 is added in the back half when body fat is low enough for its hardening and cosmetic effect to manifest visually. Combined estrogenic load is minimal — anastrozole at low frequency manages the propionate's modest aromatization. |
| Female lean cycle | Primobol Inject (50–100 mg/wk, once weekly injection, weeks 1–6) — standalone | At 50 mg/week, the enanthate ester provides steady-state methenolone levels after 2–3 weeks with minimal injection volume. The once-weekly protocol is practical and maintains stable blood levels given the ~10–14 day half-life. Most female users start at 50 mg/wk for the first 2 weeks as a virilization tolerance check before considering 100 mg/wk for weeks 3–6. Any androgenic virilization sign at any dose: reduce immediately. The compound's nitrogen retention and anti-catabolic effect at these doses supports lean muscle maintenance during a controlled caloric intake. |
Side Effects & Management
Primobol Inject has the most favorable side effect profile of any injectable AAS in the British Dragon lineup — no hepatotoxicity, no estrogenic effects, and mild androgenicity. This does not mean it is without considerations: HPG suppression, androgenic effects in predisposed users, lipid impact, and injection logistics all require appropriate management.
| What May Occur | Background | How to Handle It |
|---|---|---|
| HPG axis suppression | Methenolone suppresses LH and FSH through negative feedback on the HPG axis, as do all exogenous androgens. Suppression is generally milder than with testosterone or nandrolone at comparable doses, but it is present and meaningful at 400–600 mg/week over a 12–16 week cycle. Full HPG shutdown is less common than with testosterone-based compounds, but endogenous testosterone production is reduced enough to require PCT for full recovery. Running Primobol without a testosterone base creates an androgenic environment supported only by methenolone — functional but lower than a full testosterone stack. | Always stack with a testosterone base at replacement-level minimum (100–200 mg/wk Testabol) to cover natural testosterone function during the cycle. Full PCT after cycle conclusion — see PCT section. |
| Androgenic effects — hair, acne | Methenolone is a DHT derivative and carries androgenic activity — milder than testosterone but not zero. At 400–600 mg/week, users with androgenetic hair loss predisposition will experience accelerated loss; oily skin and mild acne occur in androgen-sensitive individuals. At the 100 mg/wk female dose, androgenic virilization (voice deepening, clitoral sensitivity, facial hair) is the primary concern — its onset is gradual and depends on individual sensitivity and cycle duration. | Acne: Isotroin (isotretinoin). Hair loss: dose reduction is the only structural mitigation. Female users: any virilization sign → reduce dose immediately; stop if symptoms persist. Some androgenic changes in women at higher doses are not fully reversible. |
| Lipid effects — mild HDL suppression | Methenolone produces a lipid profile impact that is present but milder than most other AAS. HDL suppression is documented but less pronounced than with 17α-alkylated orals or testosterone at high doses. Over a 12–16 week cycle, the cumulative effect on lipid balance warrants monitoring. The impact is substantially lower than with nandrolone, stanozolol, or the oral methenolone acetate form. | Lipid panel at baseline and mid-cycle (week 6–8). HDL below 35 mg/dL: Atorlip (atorvastatin). LDL above 130 mg/dL: same intervention. Omega-3 supplementation and dietary management throughout. |
| Injection volume at higher doses | At 100 mg/ml concentration, a 400 mg/week protocol requires 4 ml total volume per week (2 ml twice weekly or 4 ml once weekly). At 600 mg/week, this rises to 6 ml/week — a volume that warrants splitting into at least two injections to avoid discomfort and injection site irritation from large single volumes. | Split 400+ mg/wk doses into at least two weekly injections. Rotate injection sites (glutes, quads, delts). Volume tolerance can be improved with proper injection technique — slow injection rate over 30–60 seconds significantly reduces post-injection discomfort. |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| LH + FSH | Baseline; 4 weeks post-PCT | Confirm gonadotropin recovery to pre-cycle baseline. Methenolone's milder suppression typically allows faster HPG recovery than nandrolone or testosterone-heavy cycles — LH/FSH commonly recover within 4–6 weeks post-PCT. If values remain suppressed at week 8 post-PCT, extend SERM use for an additional 2 weeks. |
| Lipid panel (HDL / LDL) | Baseline; week 6–8; 6 weeks post-cycle | HDL above 35 mg/dL; LDL below 130 mg/dL. The lipid impact of methenolone is mild relative to most AAS — but over a 12–16 week cycle, cumulative HDL suppression warrants a mid-cycle check. Confirm full lipid recovery at 6 weeks post-cycle. |
| Hematocrit / CBC | Baseline; week 8 | Below 52%. Methenolone's erythropoietic effect is mild compared to nandrolone or boldenone, but present. At 400–600 mg/wk over 12+ weeks, monitoring remains appropriate. Combined with a testosterone base, the combined erythropoietic stimulus increases. |
| Blood pressure | Every 3–4 weeks | Below 130/80 mmHg. Methenolone produces no estrogen-driven fluid retention — BP elevation from this compound alone is uncommon. Monitor for the testosterone-base component's contribution. |
| Estradiol (E2) | Baseline; week 6 (if running with testosterone base) | Target 20–40 pg/mL. Only relevant if a testosterone base is included in the stack — methenolone itself contributes no aromatization. Ensure anastrozole is appropriately calibrated for the testosterone dose, not for methenolone. |
PCT — Post-Cycle Therapy
PCT begins approximately 2 weeks after the last Primobol Inject injection — the time required for the enanthate ester to clear to sub-pharmacological levels. If a testosterone enanthate base was run to the same end date, the same 2-week clearance window applies. If a testosterone propionate base was used, the propionate clears faster (~4–5 days) but the methenolone enanthate still governs the PCT start.
| Product | Role |
|---|---|
| Clomiphene Tablets BD | 50 mg/day weeks 1–2, then 25 mg/day weeks 3–4. LH/FSH stimulant. Methenolone's milder suppression means some users complete recovery in 3 weeks — post-PCT LH/FSH bloodwork at week 4–5 confirms whether a 4-week protocol was sufficient or should be extended by 1–2 weeks. |
| Tamoxifen Tablets BD | 20 mg/day weeks 1–2, then 10 mg/day weeks 3–4. Hypothalamic SERM — restores GnRH pulse frequency. Run concurrently with Clomiphene. Since methenolone does not aromatize, post-cycle estrogen levels are typically not elevated — Tamoxifen's role is gonadotropin recovery support rather than estrogenic side effect management during PCT. |
Practical Summary
- 400 mg/wk is the minimum effective dose for male users — not an advanced starting point: primobolan's reputation for mild results at low doses is accurate and well-documented. The compound requires a committed dose to work. Users running 200 mg/wk expecting results comparable to a 400 mg/wk nandrolone cycle will be disappointed — the comparison is not valid. At 400–600 mg/wk, primobolan delivers meaningful lean gains that are a different quality, not a lower quantity.
- No AI needed for methenolone itself — only manage the testosterone base: the absence of aromatization means the only estrogen management required is for the testosterone ester stacked alongside. Size the anastrozole dose to the testosterone dose only. Using higher AI doses than the testosterone component requires is unnecessary and risks estrogen suppression below the optimal range for muscle building and lipid health.
- No liver monitoring required: this is the compound where routine mid-cycle ALT/AST checks can be dropped from the protocol entirely. The only exception is if a 17α-alkylated oral is stacked — in that case, the oral drives the liver monitoring requirement, not the methenolone.
- Split injections at 400+ mg/wk: at 100 mg/ml, hitting 400 mg/wk requires 4 ml/week. Divide into two 2 ml injections (Monday/Thursday or similar). Single injections of 4 ml or more create unnecessary injection site pressure and post-injection discomfort that twice-weekly smaller volumes entirely avoid.
- PCT start is 2 weeks after the last injection: the enanthate ester governs clearance. The 10–14 day half-life means meaningful plasma levels persist for approximately 2 weeks after the last injection — starting Clomiphene and Tamoxifen while plasma methenolone is still active reduces PCT effectiveness. Wait the full 2 weeks.
- Gains are slow and fully kept — plan the cycle length accordingly: a 12-week Primobol Inject cycle will show modest visible change at week 4–6 and substantially more at week 12–16. Users accustomed to oral kickstart mass gains in weeks 1–2 find the timeline counterintuitive. The payoff is that the lean mass built over 12–16 weeks stays — it does not come with a water-loss reversal post-cycle that erases the visual progress.
Primobol Inject occupies a distinct position in the British Dragon injectable catalog — a compound where no aromatization, no hepatotoxicity, and genuinely keepable lean gains come at the cost of patience and adequate dosing. For athletes who value the quality and permanence of what they build over the speed of the initial weight gain, Steroid Warehouse carries Primobol Inject as part of the full British Dragon injectable range.
References
| Source | Description | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, establishing the anabolic effects of supraphysiologic testosterone administration | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on synthetic testosterone-derived anabolic-androgenic steroids, androgen receptor activity, oral and injectable forms, adverse effect profiles, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone, dihydrotestosterone, androgen receptor signaling, HPG-axis regulation, synthetic androgen pharmacology, aromatization, and endocrine suppression associated with exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| British Journal of Pharmacology / PubMed | Kicman AT 2008 — comprehensive review of anabolic-androgenic steroid pharmacology; covers androgen receptor binding, steroid metabolism, structural modification, ester pharmacokinetics, anabolic and androgenic mechanisms, detection methods, and adverse effects associated with AAS use | Kicman AT (2008) ↗ |
| Sports Medicine / PubMed | Hartgens F & Kuipers H 2004 — review of androgenic-anabolic steroid effects in athletes; covers strength and bodyweight changes, body composition, erythropoiesis, lipid profiles, cardiovascular effects, endocrine suppression, hepatic effects, and psychological considerations | Hartgens F & Kuipers H (2004) ↗ |
What is Primobol?
Primobol Inject is an injectable anabolic steroid (Methenolone Enanthate) for lean muscle and definition; see What is Primobol. It's mild—consult professionals for safe use.
What does Primobol do?
It promotes lean muscle, strength, and fat loss; see What Does Primobol Do. It enhances definition—monitor with labs.
How often to inject Primobolan?
Inject weekly or twice weekly (e.g., 400-800 mg/week); see How Often to Inject Primobolan. Consult professionals for protocols.
What size syringe for Primobolan injection?
Use a 3 ml syringe with 22-25 gauge needle for IM; see What Size Syringe for Primobolan Injection. Use sterile equipment—consult professionals.
How do I take Primobol?
400-800 mg/week for men, 50-100 mg/week for women, injected weekly or bi-weekly; see How to Take Primobol. Start low—consult professionals for dosing.
How to cycle Primobol?
8-12 weeks, 400-800 mg/week, PCT after 10-14 days; see How to Cycle Primobol. Stack with testosterone—consult professionals for protocols.
How does Primobol Injection work?
Primobol Injection works by promoting protein synthesis and nitrogen retention, helping support muscle preservation and gradual lean tissue development while producing minimal water retention.
What are the main benefits of Primobol Injection?
Commonly reported benefits include lean muscle retention, improved muscle definition, enhanced physique conditioning, support for strength maintenance, and a dry, aesthetic appearance.
Related Products
- Promotes lean muscle growth and strength.
- Enhances muscle definition during cutting.
- Minimizes water retention and estrogenic effects.
- Supports recovery with mild anabolic action.
- Promotes lean muscle growth and strength.
- Enhances muscle definition and hardness.
- Supports fat loss for a vascular physique.
- Delivers dry gains with minimal water retention.
